Last Updated: November 16, 2026

BIJUVA Drug Patent Profile

« Back to Dashboard


Which patents cover Bijuva, and when can generic versions of Bijuva launch?

Bijuva is a drug marketed by Mayne Pharma and is included in one NDA. There are twenty-four patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in BIJUVA is estradiol; progesterone. There is one drug master file entry for this compound. Additional details are available on the estradiol; progesterone profile page.

DrugPatentWatch® Generic Entry Outlook for Bijuva

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 21, 2032. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for BIJUVA?
  • What are the global sales for BIJUVA?
  • What is Average Wholesale Price for BIJUVA?
Summary for BIJUVA
US Patents:24
Applicants:1
NDAs:1
Drug Prices: Drug price information for BIJUVA
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for BIJUVA
What excipients (inactive ingredients) are in BIJUVA?BIJUVA excipients list
DailyMed Link:BIJUVA at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for BIJUVA
Generic Entry Date for BIJUVA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:

CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for BIJUVA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
BIJUVA Capsules estradiol; progesterone 1 mg/100 mg 210132 1 2020-01-06

US Patents and Regulatory Information for BIJUVA

BIJUVA is protected by twenty-four US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of BIJUVA is ⤷  Start Trial.

This potential generic entry date is based on patent 11,166,963.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mayne Pharma BIJUVA estradiol; progesterone CAPSULE;ORAL 210132-001 Oct 28, 2018 RX Yes Yes 11,529,360 ⤷  Start Trial Y ⤷  Start Trial
Mayne Pharma BIJUVA estradiol; progesterone CAPSULE;ORAL 210132-001 Oct 28, 2018 RX Yes Yes 11,103,513 ⤷  Start Trial ⤷  Start Trial
Mayne Pharma BIJUVA estradiol; progesterone CAPSULE;ORAL 210132-001 Oct 28, 2018 RX Yes Yes 8,993,549 ⤷  Start Trial Y ⤷  Start Trial
Mayne Pharma BIJUVA estradiol; progesterone CAPSULE;ORAL 210132-001 Oct 28, 2018 RX Yes Yes 11,793,819 ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for BIJUVA

When does loss-of-exclusivity occur for BIJUVA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 5619
Patent: FORMULACIÓN Y TERAPIAS PARA SUSTITUCIÓN HORMONAL DE COMBINACIÓN NATURAL
Estimated Expiration: ⤷  Start Trial

Patent: 8160
Patent: COMPOSICIONES FARMACÉUTICAS DE ESTRADIOL INSERTADAS EN LA VAGINA Y PROCEDIMIENTOS
Estimated Expiration: ⤷  Start Trial

Patent: 9872
Patent: FORMULACIONES DE PROGESTERONA
Estimated Expiration: ⤷  Start Trial

Patent: 7022
Patent: COMPOSICIONES FARMACÉUTICAS DE ESTRADIOL INSERTADAS POR VÍA VAGINAL Y MÉTODOS
Estimated Expiration: ⤷  Start Trial

Patent: 7914
Patent: COMPOSICIONES FARMACÉUTICAS DE ESTRADIOL INSERTADAS EN LA VAGINA Y PROCEDIMIENTOS
Estimated Expiration: ⤷  Start Trial

Australia

Patent: 12340589
Patent: Natural combination hormone replacement formulations and therapies
Estimated Expiration: ⤷  Start Trial

Patent: 13211876
Patent: Transdermal hormone replacement therapies
Estimated Expiration: ⤷  Start Trial

Patent: 13277233
Patent: Progesterone formulations
Estimated Expiration: ⤷  Start Trial

Patent: 13277234
Patent: Soluble estradiol capsule for vaginal insertion
Estimated Expiration: ⤷  Start Trial

Patent: 13277235
Patent: Transdermal hormone replacement therapies
Estimated Expiration: ⤷  Start Trial

Patent: 13277236
Patent: Natural combination hormone replacement formulations and therapies
Estimated Expiration: ⤷  Start Trial

Patent: 14349132
Patent: Vaginal inserted estradiol pharmaceutical compositons and methods
Estimated Expiration: ⤷  Start Trial

Patent: 15237243
Patent: Progesterone formulations
Estimated Expiration: ⤷  Start Trial

Patent: 16366200
Estimated Expiration: ⤷  Start Trial

Patent: 17206262
Patent: Natural Combination Hormone Replacement Formulations And Therapies
Estimated Expiration: ⤷  Start Trial

Patent: 17208300
Patent: Soluble Estradiol Capsule For Vaginal Insertion
Estimated Expiration: ⤷  Start Trial

Patent: 17394679
Patent: Natural combination hormone replacement formulations and therapies
Estimated Expiration: ⤷  Start Trial

Patent: 18222947
Patent: Progesterone Formulations
Estimated Expiration: ⤷  Start Trial

Patent: 18280270
Patent: Vaginal inserted estradiol pharmaceutical compositions and methods
Estimated Expiration: ⤷  Start Trial

Patent: 19204653
Patent: Soluble Estradiol Capsule For Vaginal Insertion
Estimated Expiration: ⤷  Start Trial

Patent: 19204655
Patent: Natural Combination Hormone Replacement Formulations And Therapies
Estimated Expiration: ⤷  Start Trial

Patent: 19204658
Patent: Vaginal Inserted Estradiol Pharmaceutical Compositions And Methods
Estimated Expiration: ⤷  Start Trial

Patent: 21218231
Patent: Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods
Estimated Expiration: ⤷  Start Trial

Patent: 21240253
Patent: Natural Combination Hormone Replacement Formulations And Therapies
Estimated Expiration: ⤷  Start Trial

Brazil

Patent: 2014012444
Patent: formulações e terapias de reposição hormonal natural combinada
Estimated Expiration: ⤷  Start Trial

Patent: 2014018439
Patent: TERAPIAS DE REPOSIÇÃO DE HORMÔNIO TRANSDÉRMICA
Estimated Expiration: ⤷  Start Trial

Patent: 2014031824
Patent: terapias de reposição hormonal transdérmica
Estimated Expiration: ⤷  Start Trial

Patent: 2014031837
Patent: formulações de progesterona
Estimated Expiration: ⤷  Start Trial

Patent: 2014031910
Patent: formulações e terapias naturais de combinação para reposição hormonal
Estimated Expiration: ⤷  Start Trial

Patent: 2014031914
Patent: cápsula de estradiol solúvel para inserção vaginal
Estimated Expiration: ⤷  Start Trial

Patent: 2016009008
Patent: USO DE ESTRADIOL E/OU HEMI-HIDRATO DE ESTRADIOL E DE UM AGENTE SOLUBILIZANTE COMPREENDENDO UM ÓLEO DE CADEIA MÉDIA PARA A PREPARAÇÃO DE UM PESSÁRIO PARA O TRATAMENTO DE ATROFIA VULVOVAGINAL E PESSÁRIO QUE COMPREENDE ESTRADIOL
Estimated Expiration: ⤷  Start Trial

Patent: 2018011483
Patent: métodos e composições farmacêuticas com estradiol vaginalmente inserido
Estimated Expiration: ⤷  Start Trial

Patent: 2019011655
Patent: fórmulas e terapias naturais combinadas para reposição
Estimated Expiration: ⤷  Start Trial

Patent: 2019025914
Patent: composições farmacêuticas de estradiol para inserção vaginal e métodos
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 56520
Patent: PREPARATIONS ET THERAPIES DE SUBSTITUTION POUR HORMONOTHERAPIE NATURELLE COMBINEE (NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES)
Estimated Expiration: ⤷  Start Trial

Patent: 61346
Patent: THERAPIES TRANSDERMIQUES DE REMPLACEMENT D'HORMONE (TRANSDERMAL HORMONE REPLACEMENT THERAPIES)
Estimated Expiration: ⤷  Start Trial

Patent: 76947
Patent: TRAITEMENT TRANSDERMIQUE DE SUBSTITUTION HORMONALE (TRANSDERMAL HORMONE REPLACEMENT THERAPIES)
Estimated Expiration: ⤷  Start Trial

Patent: 76964
Patent: FORMULATIONS DE PROGESTERONE (PROGESTERONE FORMULATIONS)
Estimated Expiration: ⤷  Start Trial

Patent: 76968
Patent: CAPSULE D'ESTRADIOL SOLUBLE POUR INSERTION VAGINALE (SOLUBLE ESTRADIOL CAPSULE FOR VAGINAL INSERTION)
Estimated Expiration: ⤷  Start Trial

Patent: 76977
Patent: FORMULATIONS ET THERAPIES DE REMPLACEMENT D'HORMONES DE COMBINAISON NATURELLE (NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES)
Estimated Expiration: ⤷  Start Trial

Patent: 26342
Patent: COMPOSITIONS PHARMACEUTIQUES A BASE D'ESTRADIOL POUR INSERTION VAGINALE ET METHODES ASSOCIEES (VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITONS AND METHODS)
Estimated Expiration: ⤷  Start Trial

Patent: 42568
Patent: FORMULATIONS DE PROGESTERONE (PROGESTERONE FORMULATIONS)
Estimated Expiration: ⤷  Start Trial

Patent: 07636
Patent: COMPOSITIONS PHARMACEUTIQUES A BASE D'OESTRADIOL INTRODUITES PAR VOIE VAGINALE ET PROCEDES ASSOCIES (VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODS)
Estimated Expiration: ⤷  Start Trial

Patent: 45024
Patent: THERAPIES ET FORMULATIONS HORMONALES DE SUBSTITUTION COMBINATOIRES NATURELLES (NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES)
Estimated Expiration: ⤷  Start Trial

China

Patent: 0290793
Patent: 天然组合激素替代制剂和治疗 (NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES)
Estimated Expiration: ⤷  Start Trial

Croatia

Patent: 0210861
Estimated Expiration: ⤷  Start Trial

Patent: 0211377
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 82584
Patent: PRÉPARATIONS ET THÉRAPIES DE SUBSTITUTION POUR HORMONOTHÉRAPIE NATURELLE COMBINÉE (NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES)
Estimated Expiration: ⤷  Start Trial

Patent: 06742
Patent: THÉRAPIES TRANSDERMIQUES DE REMPLACEMENT D'HORMONE (TRANSDERMAL HORMONE REPLACEMENT THERAPIES)
Estimated Expiration: ⤷  Start Trial

Patent: 61072
Patent: FORMULATIONS ET THÉRAPIES DE REMPLACEMENT D'HORMONES DE COMBINAISON NATURELLE (NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES)
Estimated Expiration: ⤷  Start Trial

Patent: 61073
Patent: CAPSULE D'ESTRADIOL SOLUBLE POUR INSERTION VAGINALE (SOLUBLE ESTRADIOL CAPSULE FOR VAGINAL INSERTION)
Estimated Expiration: ⤷  Start Trial

Patent: 61233
Patent: TRAITEMENT TRANSDERMIQUE DE SUBSTITUTION HORMONALE (TRANSDERMAL HORMONE REPLACEMENT THERAPIES)
Estimated Expiration: ⤷  Start Trial

Patent: 61234
Patent: FORMULATIONS DE PROGESTÉRONE (PROGESTERONE FORMULATIONS)
Estimated Expiration: ⤷  Start Trial

Patent: 60179
Patent: COMPOSITIONS PHARMACEUTIQUES À BASE D'ESTRADIOL POUR INSERTION VAGINALE ET MÉTHODES ASSOCIÉES (VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITONS AND METHODS)
Estimated Expiration: ⤷  Start Trial

Patent: 22364
Patent: FORMULATIONS DE PROGESTÉRONE (PROGESTERONE FORMULATIONS)
Estimated Expiration: ⤷  Start Trial

Patent: 86514
Patent: COMPOSITIONS PHARMACEUTIQUES À BASE D' STRADIOL INTRODUITES PAR VOIE VAGINALE ET PROCÉDÉS ASSOCIÉS (VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODS)
Estimated Expiration: ⤷  Start Trial

Patent: 48036
Patent: THÉRAPIES ET FORMULATIONS HORMONALES DE SUBSTITUTION COMBINATOIRES NATURELLES (NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES)
Estimated Expiration: ⤷  Start Trial

Patent: 60500
Patent: FORMULATIONS DE PROGESTÉRONE (PROGESTERONE FORMULATIONS)
Estimated Expiration: ⤷  Start Trial

Patent: 09586
Patent: CAPSULE D' STRADIOL SOLUBLE POUR INSERTION VAGINALE (SOLUBLE ESTRADIOL CAPSULE FOR VAGINAL INSERTION)
Estimated Expiration: ⤷  Start Trial

Patent: 36133
Patent: PRÉPARATIONS ET THÉRAPIES DE SUBSTITUTION POUR HORMONOTHÉRAPIE NATURELLE COMBINÉE (NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES)
Estimated Expiration: ⤷  Start Trial

Patent: 09646
Patent: FORMULATIONS ET THÉRAPIES DE REMPLACEMENT D'HORMONES COMBINÉES NATURELLES (NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES)
Estimated Expiration: ⤷  Start Trial

France

Patent: C1058
Estimated Expiration: ⤷  Start Trial

Hungary

Patent: 55275
Estimated Expiration: ⤷  Start Trial

Patent: 55562
Estimated Expiration: ⤷  Start Trial

Israel

Patent: 6358
Patent: תכשירים תרופתיים המכילים תחליפי הורמונים והשימוש בהם (Pharmaceutical compositions comprising hormone replacement formulations and uses thereof)
Estimated Expiration: ⤷  Start Trial

Patent: 6359
Patent: קפסולת אסטראדיול מסיס להחדרה וגינאלית (Soluble estradiol capsule for vaginal insertion)
Estimated Expiration: ⤷  Start Trial

Patent: 5139
Patent: שיטות והרכבים פרמצבטיים של אסטרדיול להחדרה וגינלית (Vaginal inserted estradiol pharmaceutical compositions and methods)
Estimated Expiration: ⤷  Start Trial

Patent: 9884
Patent: הרכבי אסתרדיול תרופתיים להכנסה וגינלית ושיטות שימוש בהם (Vaginal inserted estradiol pharmaceutical compositions and methods)
Estimated Expiration: ⤷  Start Trial

Patent: 7023
Patent: פורמולציות של תחליף טבעי של שילובי הורמונים וטיפולים בעזרתן (Natural combination hormone replacement formulations and therapies)
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 24393
Estimated Expiration: ⤷  Start Trial

Patent: 85866
Estimated Expiration: ⤷  Start Trial

Patent: 98460
Estimated Expiration: ⤷  Start Trial

Patent: 34519
Estimated Expiration: ⤷  Start Trial

Patent: 42334
Estimated Expiration: ⤷  Start Trial

Patent: 42389
Estimated Expiration: ⤷  Start Trial

Patent: 97402
Estimated Expiration: ⤷  Start Trial

Patent: 56215
Estimated Expiration: ⤷  Start Trial

Patent: 80672
Estimated Expiration: ⤷  Start Trial

Patent: 82127
Estimated Expiration: ⤷  Start Trial

Patent: 98177
Estimated Expiration: ⤷  Start Trial

Patent: 15504924
Patent: 経皮ホルモン補充療法
Estimated Expiration: ⤷  Start Trial

Patent: 15507607
Patent: 天然複合ホルモン補充製剤および療法
Estimated Expiration: ⤷  Start Trial

Patent: 15519405
Patent: 膣内挿入用可溶性エストラジオールカプセル
Estimated Expiration: ⤷  Start Trial

Patent: 15520235
Patent: プロゲステロン製剤
Estimated Expiration: ⤷  Start Trial

Patent: 15520236
Patent: 経皮的ホルモン補充療法
Estimated Expiration: ⤷  Start Trial

Patent: 15520237
Patent: 天然の併用ホルモン補充療法剤及び治療
Estimated Expiration: ⤷  Start Trial

Patent: 16534025
Patent: 膣挿入されるエストラジオール薬学的組成物及び方法
Estimated Expiration: ⤷  Start Trial

Patent: 17509630
Patent: プロゲステロン製剤
Estimated Expiration: ⤷  Start Trial

Patent: 18024685
Patent: 天然複合ホルモン補充製剤および療法 (NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES)
Estimated Expiration: ⤷  Start Trial

Patent: 18024688
Patent: 天然の併用ホルモン補充療法剤及び治療 (NATURAL COMBINATION HORMONE REPLACEMENT THERAPY AGENTS AND THERAPIES)
Estimated Expiration: ⤷  Start Trial

Patent: 18199711
Patent: 膣内挿入用可溶性エストラジオールカプセル (SOLUBLE ESTRADIOL CAPSULE FOR VAGINAL INSERTION)
Estimated Expiration: ⤷  Start Trial

Patent: 18538290
Patent: 膣挿入エストラジオール医薬組成物および方法
Estimated Expiration: ⤷  Start Trial

Patent: 19206540
Patent: プロゲステロン製剤 (PROGESTERONE FORMULATIONS)
Estimated Expiration: ⤷  Start Trial

Patent: 19214598
Patent: 天然の併用ホルモン補充療法剤及び治療 (NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES)
Estimated Expiration: ⤷  Start Trial

Patent: 20100642
Patent: 膣内挿入用可溶性エストラジオールカプセル (SOLUBLE ESTRADIOL CAPSULE FOR VAGINAL INSERTION)
Estimated Expiration: ⤷  Start Trial

Patent: 20504093
Patent: 天然配合ホルモン補充製剤及び治療法
Estimated Expiration: ⤷  Start Trial

Patent: 21119155
Patent: 膣挿入エストラジオール医薬組成物および方法 (VAGINAL INSERTION ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODS)
Estimated Expiration: ⤷  Start Trial

Lithuania

Patent: 82584
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 8435
Estimated Expiration: ⤷  Start Trial

Patent: 5818
Estimated Expiration: ⤷  Start Trial

Patent: 7596
Estimated Expiration: ⤷  Start Trial

Patent: 3208
Estimated Expiration: ⤷  Start Trial

Patent: 4850
Estimated Expiration: ⤷  Start Trial

Patent: 3195
Estimated Expiration: ⤷  Start Trial

Patent: 14006256
Estimated Expiration: ⤷  Start Trial

Patent: 14009093
Estimated Expiration: ⤷  Start Trial

Patent: 14015897
Estimated Expiration: ⤷  Start Trial

Patent: 14015898
Estimated Expiration: ⤷  Start Trial

Patent: 14015899
Estimated Expiration: ⤷  Start Trial

Patent: 14015900
Estimated Expiration: ⤷  Start Trial

Patent: 16005092
Estimated Expiration: ⤷  Start Trial

Patent: 16011706
Estimated Expiration: ⤷  Start Trial

Patent: 18006882
Estimated Expiration: ⤷  Start Trial

Patent: 19006513
Estimated Expiration: ⤷  Start Trial

Patent: 20013533
Estimated Expiration: ⤷  Start Trial

Patent: 22002614
Estimated Expiration: ⤷  Start Trial

Poland

Patent: 82584
Estimated Expiration: ⤷  Start Trial

Patent: 61072
Estimated Expiration: ⤷  Start Trial

Patent: 61073
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 82584
Estimated Expiration: ⤷  Start Trial

Patent: 61072
Estimated Expiration: ⤷  Start Trial

Russian Federation

Patent: 13888
Estimated Expiration: ⤷  Start Trial

Patent: 40059
Patent: КАПСУЛЫ С РАСТВОРИМЫМ ЭСТРАДИОЛОМ ДЛЯ ИНТРАВАГИНАЛЬНОГО ВВЕДЕНИЯ (CAPSULES WITH SOLUBLE OESTRADIOL FOR INTRAVAGINAL INTRODUCTION)
Estimated Expiration: ⤷  Start Trial

Patent: 15100531
Patent: КАПСУЛЫ С РАСТВОРИМЫМ ЭСТРАДИОЛОМ ДЛЯ ИНТРАВАГИНАЛЬНОГО ВВЕДЕНИЯ (CAPSULES WITH SOLUBLE OESTRADIOL FOR INTRAVAGINAL INTRODUCTION)
Estimated Expiration: ⤷  Start Trial

Patent: 15100533
Patent: ЕСТЕСТВЕННАЯ КОМБИНАЦИЯ СОСТАВОВ И СПОСОБОВ ГОРМОНОЗАМЕСТИТЕЛЬНОЙ ТЕРАПИИ
Estimated Expiration: ⤷  Start Trial

Patent: 16118396
Patent: ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ И СПОСОБЫ НА ОСНОВЕ ЭСТРАДИОЛА ДЛЯ ИНТРАВАГИНАЛЬНОГО ВВЕДЕНИЯ (PHARMACEUTICAL COMPOSITIONS AND METHODS BASED ON OESTRADIOL FOR INTRAVAGINAL INTRODUCTION)
Estimated Expiration: ⤷  Start Trial

Patent: 16136666
Patent: СОСТАВЫ НА ОСНОВЕ ПРОГЕСТЕРОНА
Estimated Expiration: ⤷  Start Trial

Patent: 19115913
Patent: ПРИРОДНЫЕ КОМБИНИРОВАННЫЕ ГОРМОНОЗАМЕСТИТЕЛЬНЫЕ СОСТАВЫ И СПОСОБЫ ТЕРАПИИ
Estimated Expiration: ⤷  Start Trial

Patent: 19139675
Patent: ВАГИНАЛЬНЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ЭСТРАДИОЛ, И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
Estimated Expiration: ⤷  Start Trial

Patent: 19142696
Patent: ЕСТЕСТВЕННАЯ КОМБИНАЦИЯ СОСТАВОВ И СПОСОБОВ ГОРМОНОЗАМЕСТИТЕЛЬНОЙ ТЕРАПИИ
Estimated Expiration: ⤷  Start Trial

Patent: 20140867
Patent: КАПСУЛЫ С РАСТВОРИМЫМ ЭСТРАДИОЛОМ ДЛЯ ИНТРАВАГИНАЛЬНОГО ВВЕДЕНИЯ
Estimated Expiration: ⤷  Start Trial

Serbia

Patent: 297
Patent: PRIRODNE KOMBINOVANE HORMONSKE SUPSTITUCIONE FORMULACIJE I TERAPIJE (NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES)
Estimated Expiration: ⤷  Start Trial

South Africa

Patent: 1500212
Patent: PROGESTERONE FORMULATIONS
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 2163369
Estimated Expiration: ⤷  Start Trial

Patent: 2177782
Estimated Expiration: ⤷  Start Trial

Patent: 2335160
Estimated Expiration: ⤷  Start Trial

Patent: 2488424
Estimated Expiration: ⤷  Start Trial

Patent: 150028302
Patent: 천연 병용 호르몬 대체 제형 및 요법 (NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES)
Estimated Expiration: ⤷  Start Trial

Patent: 150032560
Patent: 질 삽입용 가용성 에스트라디올 캡슐 (SOLUBLE ESTRADIOL CAPSULE FOR VAGINAL INSERTION)
Estimated Expiration: ⤷  Start Trial

Patent: 160062097
Patent: 질내 삽입형 에스트라다이올 약제학적 조성물 및 방법 (VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITONS AND METHODS)
Estimated Expiration: ⤷  Start Trial

Patent: 160137597
Estimated Expiration: ⤷  Start Trial

Patent: 180100567
Estimated Expiration: ⤷  Start Trial

Patent: 200013771
Estimated Expiration: ⤷  Start Trial

Patent: 200018383
Estimated Expiration: ⤷  Start Trial

Patent: 200128214
Estimated Expiration: ⤷  Start Trial

Patent: 210107915
Estimated Expiration: ⤷  Start Trial

Patent: 210148435
Estimated Expiration: ⤷  Start Trial

Patent: 220080205
Estimated Expiration: ⤷  Start Trial

Patent: 230021170
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 69250
Estimated Expiration: ⤷  Start Trial

Patent: 85523
Estimated Expiration: ⤷  Start Trial

Patent: 67709
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BIJUVA around the world.

Country Patent Number Title Estimated Expiration
Argentina 095619 ⤷  Start Trial
Argentina 098160 ⤷  Start Trial
Argentina 099872 ⤷  Start Trial
Argentina 107022 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for BIJUVA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0398460 C300221 Netherlands ⤷  Start Trial PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
0334429 97C0002 Belgium ⤷  Start Trial PRODUCT NAME: ESTRADIOL; NAT. REGISTRATION NO/DATE: NL 18978 19960731; FIRST REGISTRATION: SE - 11783 19930305
1214076 C01214076/01 Switzerland ⤷  Start Trial PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
1453521 122015000093 Germany ⤷  Start Trial PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

BIJUVA Market Dynamics, Patent Position, and Financial Trajectory

Last updated: October 18, 2026

BIJUVA is an oral fixed-dose combination of estradiol and progesterone approved for moderate-to-severe vasomotor symptoms associated with menopause in women with an intact uterus. Its commercial proposition is the combination of bioidentical hormones in a single prescription capsule. The product operates in a competitive market where lower-cost generic estradiol and micronized progesterone are widely available separately.

BIJUVA’s commercial growth has depended on physician adoption, insurance coverage, menopause-treatment demand, and the ability to justify a branded combination price. TherapeuticsMD developed and launched the product, while Mayne Pharma became the U.S. commercial owner after acquiring key TherapeuticsMD assets. Financial performance improved from a low launch base but remained exposed to the economics of a specialty branded product competing against inexpensive generic alternatives.

What is BIJUVA and who owns the product?

BIJUVA contains 1 mg of estradiol and 100 mg of progesterone in an oral softgel capsule. The product is indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause in women with a uterus.[1]

Item Detail
Brand BIJUVA
Active ingredients Estradiol and progesterone
Dosage form Oral softgel capsule
Strength 1 mg estradiol / 100 mg progesterone
FDA application NDA 210166
U.S. approval October 2018
Initial developer TherapeuticsMD, Inc.
Current U.S. commercial owner Mayne Pharma
Therapeutic area Menopausal hormone therapy
Primary indication Moderate-to-severe vasomotor symptoms
Key commercial distinction Fixed-dose oral estradiol-progesterone combination

TherapeuticsMD launched BIJUVA in 2019. Mayne Pharma acquired the U.S. commercial rights to BIJUVA and other women’s-health products from TherapeuticsMD as part of its expansion in the U.S. pharmaceutical market.[2]

How large is the BIJUVA market?

The addressable market is large, but BIJUVA’s branded opportunity is narrower. Millions of women experience menopausal symptoms, yet only a minority receive systemic hormone therapy. Treatment decisions depend on symptom severity, age, contraindications, patient preference, and physician practice.

BIJUVA competes in three overlapping markets:

  1. Oral systemic hormone therapy.
  2. Combination estrogen-progestogen therapy for women with an intact uterus.
  3. Branded menopause products positioned around convenience and bioidentical ingredients.

The most important commercial substitute is not another branded fixed-dose product. It is the separate prescription of generic estradiol and generic micronized progesterone. Physicians can adjust the dose of each component and patients often face lower out-of-pocket costs.

Other branded competitors include Prempro, Premphase, Activella, Combipatch, and Bijuva-like compounded or individually prescribed regimens. Duavee, which combines conjugated estrogens and bazedoxifene, competes for patients seeking a non-progestogen endometrial-protection strategy.

What drives BIJUVA demand?

BIJUVA demand is influenced by:

  • Increased recognition of menopause as a treatable medical condition.
  • Greater physician and patient interest in FDA-approved bioidentical hormone therapy.
  • The convenience of one capsule instead of two prescriptions.
  • Coverage and formulary placement.
  • Patient persistence with oral hormone therapy.
  • Marketing to obstetrician-gynecologists, primary-care physicians, and menopause specialists.

The product’s main weakness is that its convenience premium can be difficult to sustain when generic components are substantially cheaper.

What is the financial trajectory for BIJUVA?

BIJUVA moved from launch-stage revenue to a more established branded product during TherapeuticsMD’s commercialization period. The company reported increasing product sales as distribution expanded, although the product remained part of a broader portfolio that included ANNOVERA and other women’s-health assets.[3]

The financial trajectory can be divided into four phases:

Phase Period Financial characteristics
Development and approval 2015-2018 High development and regulatory costs; no product revenue
Launch 2019 Initial revenue generation and promotional investment
Commercial expansion 2020-2022 Higher prescriptions and distribution; continued selling expenses
Portfolio transition 2022 onward Commercial ownership shifted to Mayne Pharma; performance evaluated within Mayne’s women’s-health portfolio

TherapeuticsMD’s public filings show that BIJUVA revenue increased after launch, but the product did not by itself resolve the company’s broader liquidity and financing pressures. TherapeuticsMD pursued strategic alternatives and asset transactions as it sought to reduce debt and improve its capital position.[3]

Mayne Pharma’s financial reporting places BIJUVA within its U.S. commercial and women’s-health operations rather than presenting the product as a separately reported public-company segment in every reporting period. This limits the precision of public revenue analysis. The relevant indicators are product revenue, prescription growth, gross margin, selling expense, payer mix, and the contribution of BIJUVA to the women’s-health portfolio.[2]

What is BIJUVA’s revenue exposure?

BIJUVA’s revenue exposure is meaningful for Mayne Pharma’s U.S. women’s-health strategy but modest relative to the company’s total pharmaceutical portfolio. The principal risks are:

  • Substitution by generic estradiol and progesterone.
  • Reimbursement restrictions.
  • Higher patient copayments.
  • Limited differentiation beyond fixed-dose convenience.
  • Generic or authorized-generic entry after relevant protection expires.
  • Promotional costs required to maintain physician awareness.

A successful commercial strategy requires maintaining a price premium without losing patients to separate generic prescriptions.

What patents protect BIJUVA?

BIJUVA protection is based primarily on patents covering the combined estradiol-progesterone formulation, pharmaceutical composition, dosage form, and related manufacturing or use concepts. FDA Orange Book listings, rather than marketing materials, control the operative U.S. patent record.[4]

The product’s patent position should be analyzed across four categories:

Composition and formulation patents

These patents may cover the presence of estradiol and progesterone in defined amounts, excipient systems, capsule architecture, and physicochemical properties. They are commercially important because they can block a directly substitutable fixed-dose capsule even when the individual ingredients are old.

Method-of-use patents

BIJUVA’s FDA-approved use is menopausal hormone therapy for vasomotor symptoms. Method-of-use claims can create litigation leverage if an abbreviated new drug application relies on the same indication. Their practical value depends on claim scope, enforceability, and the availability of non-infringing labeling.

Manufacturing patents

Manufacturing protection may address uniformity, dissolution, hormone dispersion, capsule fill, or stability. These rights can complicate development but usually create less durable commercial protection than a broad composition patent.

Regulatory exclusivity

BIJUVA was approved in October 2018 as a new combination product. The product’s regulatory exclusivity is distinct from patent protection. The relevant exclusivity period for a new drug combination is generally shorter than the patent term and does not prevent later approval once the statutory requirements are met.[5]

When does BIJUVA lose exclusivity?

BIJUVA’s five-year new chemical entity exclusivity does not apply in the same manner as it would to a drug containing a previously unapproved active moiety. Estradiol and progesterone were established active ingredients before BIJUVA approval. The product’s regulatory protection therefore depends on the applicable new-drug application exclusivity, Orange Book-listed patents, pediatric exclusivity if granted, and any litigation-related stay.

A definitive generic-entry analysis requires the current FDA Orange Book record and the status of any listed patent litigation. The commercial loss-of-exclusivity date cannot be inferred from the 2018 approval date alone.

Generic entry could occur through:

  • An ANDA referencing BIJUVA.
  • A Paragraph IV certification challenging listed patents.
  • A product with different labeling that avoids protected methods of use.
  • Separate generic estradiol and progesterone prescriptions, which already provide a substitute regimen.

What is the Orange Book status of BIJUVA?

BIJUVA is listed in the FDA’s Drugs@FDA database under NDA 210166. The Orange Book identifies the approved product, therapeutic equivalence information, patents submitted by the NDA holder, and applicable exclusivity information.[1,4]

The commercial significance of the Orange Book record is limited by the product’s therapeutic substitution profile. Even without a directly substitutable generic capsule, physicians can prescribe the two generic hormones separately. That creates effective competitive pressure before formal generic entry.

Patent listing, expiration, and litigation status must be reviewed together. A patent may be listed but provide limited practical protection if its claims are narrow, vulnerable to invalidity challenges, or easy to design around.

Which companies are challenging BIJUVA?

Publicly available information through mid-2024 does not establish a major, publicly adjudicated Paragraph IV challenge that has materially changed BIJUVA’s market outlook. Generic-drug companies remain potential challengers because the active ingredients are established and the principal commercial barrier is the fixed-dose combination.

A Paragraph IV challenge would likely focus on:

  • Obviousness of combining estradiol and progesterone.
  • Written description and enablement.
  • Claim scope covering the particular softgel formulation.
  • Patent expiration or listing deficiencies.
  • The ability to market with restricted labeling.

A successful challenge could accelerate generic entry. A settlement could delay entry until an agreed date while preserving some period of branded sales.

What litigation and settlement risks affect BIJUVA?

BIJUVA’s litigation risk is lower than that of a blockbuster product with billions of dollars in annual sales, but the economics can still support patent litigation if the branded product generates durable revenue and the generic opportunity is attractive.

Key litigation scenarios include:

Scenario Commercial result
Patent holder wins Generic entry may be delayed until patent expiry
Generic prevails Earlier fixed-dose competition and rapid price erosion
Settlement with licensed entry Entry occurs on an agreed date, often before patent expiry
No direct ANDA challenge Competition still expands through separate generic prescriptions
Narrow-label generic Limited substitution may reduce immediate erosion

No material settlement should be assumed unless it appears in FDA, federal court, SEC, or company disclosures.

How does BIJUVA compare with generic estradiol plus progesterone?

Attribute BIJUVA Separate generic estradiol plus progesterone
Dosing One capsule Two products
Dose flexibility Limited to approved fixed strength High
Cost Branded price Usually substantially lower
FDA-approved combination Yes No fixed-dose combination
Adherence convenience Higher Lower
Payer friction Often higher Usually lower
Generic substitution Depends on Orange Book status Widely available
Commercial differentiation Convenience and formulation Price and flexibility

BIJUVA’s strongest defense is convenience. Its weakest defense is cost.

What generic entry risks exist for BIJUVA?

The highest-probability erosion pathway is therapeutic substitution rather than immediate direct generic substitution. A physician can prescribe generic estradiol and micronized progesterone today, creating price competition even while BIJUVA remains protected as a branded combination.

Direct generic entry would likely produce:

  • Lower average selling prices.
  • Higher payer pressure.
  • Reduced branded prescription volume.
  • Greater switching by price-sensitive patients.
  • Increased reliance on adherence and convenience messaging.

Revenue erosion would depend on whether a generic capsule is therapeutically substitutable, whether insurers place it on preferred tiers, and whether Mayne Pharma retains a meaningful price differential.

How strong is the BIJUVA patent estate?

BIJUVA’s patent estate is commercially moderate rather than dominant. The active ingredients are old, which limits the scope of protection available for the underlying pharmacology. The defensible value lies in the fixed-dose formulation, delivery system, manufacturing process, and approved combination.

Patent strength is therefore shaped by:

  • Breadth of formulation claims.
  • Number and expiration dates of listed patents.
  • Validity under obviousness standards.
  • Ease of designing around the capsule composition.
  • Availability of separate generic component therapy.
  • Potential for non-infringing generic labeling.

The product has a stronger commercial position against an identical combination capsule than against separate generic hormone therapy.

What is the FDA regulatory status of BIJUVA?

BIJUVA is FDA-approved under NDA 210166 for moderate-to-severe vasomotor symptoms associated with menopause in women with an intact uterus.[1] It is a prescription systemic hormone therapy and carries class-specific estrogen and progestogen risks, including boxed-warning concerns relating to cardiovascular events, malignancy, and dementia in certain populations.

Regulatory factors affecting demand include:

  • FDA-approved labeling versus compounded hormone therapy.
  • Contraindications and boxed warnings.
  • Duration and dose recommendations.
  • Patient age and time since menopause.
  • Physician adherence to individualized risk-benefit assessment.
  • Renewed attention to menopause treatment after updated clinical discussions.

FDA approval gives BIJUVA a regulatory-quality advantage over compounded products, but it does not eliminate payer or price barriers.

How do licensing and ownership changes affect BIJUVA?

The transfer from TherapeuticsMD to Mayne Pharma changed the product’s commercial context. TherapeuticsMD developed the product and bore the initial launch costs. Mayne Pharma acquired commercial rights and integrated BIJUVA into its U.S. pharmaceutical platform.[2]

The transaction may improve commercial efficiency through:

  • A broader sales infrastructure.
  • Existing payer and distributor relationships.
  • Portfolio-level promotion.
  • Lower standalone infrastructure requirements.
  • Better alignment with Mayne Pharma’s women’s-health strategy.

The transaction does not remove the product’s core risks: generic component competition, payer restrictions, and the need to maintain physician demand.

Key Takeaways

  • BIJUVA is a branded fixed-dose oral combination of estradiol and progesterone.
  • Its main commercial advantage is one-capsule convenience and FDA-approved combination labeling.
  • Its main competitive threat is generic estradiol plus generic micronized progesterone.
  • TherapeuticsMD launched BIJUVA; Mayne Pharma later acquired U.S. commercial rights.
  • Public filings show commercial expansion from launch, but BIJUVA remained part of a broader portfolio and was not a standalone blockbuster.
  • Patent value rests on formulation, combination, delivery, and manufacturing claims rather than new active ingredients.
  • Direct Paragraph IV activity has not publicly established a major change in the product’s market position through mid-2024.
  • Effective competition already exists through separate generic prescriptions.
  • Revenue durability depends on reimbursement, adherence, convenience, and the absence of an early fixed-dose generic.

FAQs

Is BIJUVA considered bioidentical hormone therapy?

Yes. BIJUVA contains estradiol and progesterone that are chemically identical to hormones produced naturally by the human body. It is an FDA-approved product, unlike many compounded hormone preparations.

Is BIJUVA more effective than taking estradiol and progesterone separately?

BIJUVA provides the same core hormonal components in a fixed-dose capsule. Its primary demonstrated advantage is convenience and an FDA-approved combination regimen, not necessarily superior pharmacologic efficacy compared with appropriately dosed separate products.

Can a generic version of BIJUVA be substituted automatically?

Automatic substitution depends on FDA therapeutic-equivalence status, state pharmacy law, payer policy, and the availability of an approved generic referencing BIJUVA. Separate generic estradiol and progesterone are not automatically equivalent to the fixed-dose BIJUVA capsule.

Does BIJUVA have pediatric exclusivity?

No publicly established pediatric exclusivity period is central to the product’s commercial outlook through mid-2024. The applicable FDA exclusivity and patent record should be read from current regulatory databases.

What is the biggest long-term risk to BIJUVA sales?

The largest risk is price substitution by generic estradiol and progesterone, even without an identical generic capsule. That pressure can limit pricing power, reimbursement, and prescription growth.

References

  1. U.S. Food and Drug Administration. (2018). BIJUVA (estradiol and progesterone) prescribing information and NDA 210166.
  2. Mayne Pharma Group Limited. (2022-2024). Annual reports and investor disclosures.
  3. TherapeuticsMD, Inc. (2019-2022). Form 10-K and Form 10-Q filings. U.S. Securities and Exchange Commission.
  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
  5. U.S. Food and Drug Administration. (2024). Small business and industry assistance: Abbreviated new drug application and exclusivity provisions.

More… ↓

⤷  Start Trial

DrugChatter Q&A for BIJUVA

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.